Killing Prostate Cancer Cells and Endothelial Cells With a VEGF-Triggered Cell Death Receptor
Abstract
The purpose of this project is to use a novel chimeric cell death receptor (termed R2Fas) that is triggered by vascular endothelial growth factor (VEGF), as a means to kill prostate cancer ells and vascular endothelial cells. The scope of this project involves: (i) creating adenoviral reagents to express the R2Fas receptor in prostate cancer cells and endothelial cells; (ii) determining if the R2Fas receptor kills cells in a VEGF-dependent manner; and (iii) identifying methods for increasing the killing activity of R2Fas. The major findings to date include: (i) we have generated adenoviral reagents to express R2Fas as well as control adenoviruses; (ii) we have demonstrated that adenoviral-mediated expression of R2Fas in prostate cancer cells that overexpress VEGF activates apoptotic signaling and induces cell death; (iii) we have demonstrated that adenoviral-mediated expression of R2Fas in human endothelial cell is non-toxic, but renders the cells sensitive to killing when treated with VEGF and (iv) we have demonstrated that R2Fas- mediated apoptosis can be potentiated by addition of several pharmacologic agents.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2004
- Accession Number
- ADA423810
Entities
People
- Timothy P. Quinn
Organizations
- University of California, San Francisco